Compare Amgen, Inc. (AMGN) vs abrdn Physical Palladium Shares ETF (PALL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amgen, Inc. vs abrdn Physical Palladium Shares ETF — how do they compare? Amgen, Inc. trades at $356.4 (market cap $196.12B), while abrdn Physical Palladium Shares ETF trades at $22.83. The key difference: Amgen, Inc. pays a 2.77% dividend while abrdn Physical Palladium Shares ETF pays none, and Amgen, Inc. is trading nearer its 52-week high, abrdn Physical Palladium Shares ETF nearer its low. Which is the better fit depends on your goals.
| AMGN | PALL | |
|---|---|---|
Market Cap | $196.12B | — |
Sector | Health | Commodities - Metals/Agriculture |
52-Week High | $388.16 | $37.18 |
52-Week Low | $271.18 | $19.96 |
Enterprise Value | $241.41B | — |
Dividend Yield | 2.77% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
PALL (abrdn Physical Palladium Shares ETF) trades at $23.07, up 1.63% with bearish technical signals from moving averages but neutral oscillators. The ETF recently underwent a 5-for-1 stock split effective May 18, 2026. Financial ratios are unavailable, but palladium's 47% price decline from January 2026 highs has drawn attention as a potential catch-up trade amid broader precious metals strength.
The outlook hinges on palladium's supply-demand dynamics, with Seeking Alpha highlighting a buying opportunity at current levels due to industrial demand and supply risks. Key risks include Federal Reserve policy impacts and commodity volatility. Analyst sentiment is cautiously optimistic, viewing the price weakness as a potential entry point for exposure to palladium's recovery prospects.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About abrdn Physical Palladium Shares ETF
PALL is a physically-backed ETF that tracks the spot price of palladium. It holds physical bullion in secure vaults, offering a liquid way to invest in this precious metal primarily used in automotive catalytic converters and electronics.
Read more on PALL →
